Leitlinie der Arbeitsgruppe Allergologie der ?GDV – Provokationstestungen zur Abkl?rung von unerwünschten Arzneireaktionen an Haut und Schleimh?uten

摘要

Nowadays, clinical and evidence based guidelines are considered one of the major efforts to improve patient care in medical practices as well as hospital settings. In the literature, clinical guidelines have been defined as "systematically developed statements to assist practitioner and patient decisions about appropriate healthcare for specific clinical circumstances", which promote both clinically effective standards and cost-effective care [1–4]. Despite controversial discussion about the clinical impact of guidelines [5, 6], they may provide workable recommendations that may thus be important for improving the individual patient's care [1, 4]. Adverse drug reactions (drug allergies, drug hypersensitivities) often represent a major hazard for the affected patient, and a definite diagnosis is important for further drug therapies in most cases. In this context, any diagnostic procedure must be preceded by an individual risk-benefit assessment. Drug provocation testing is regarded as the gold standard, but this kind of testing should be performed in accordance with established criteria and, in the vast majority of cases, in a hospital setting. In this paper we present a clinical guideline for drug provocation testing in Austria.